scholarly journals The Cost Study of First- line Treatment of Metastatic Colorectal Carcinoma with Bevacizumab- containing Regimen in the Czech Republic

2014 ◽  
Vol 27 (4) ◽  
pp. 255-260
Author(s):  
Irena Hradecká ◽  
Barbora Říhová ◽  
Renata Horová ◽  
Regina Demlová
Keyword(s):  
Czech Republic ◽  
Colorectal Carcinoma ◽  
Line Treatment ◽  
Metastatic Colorectal Carcinoma ◽  
First Line ◽  
Cost Study ◽  
The Czech Republic ◽  
The Cost ◽  
First Line Treatment

Phase II study of capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal carcinoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15125-e15125
Author(s):  
R. Xu none ◽  
Y. Li ◽  
H. Luo ◽  
F. Wang
Keyword(s):  
Colorectal Carcinoma ◽  
Maintenance Therapy ◽  
Healthcare Providers ◽  
Progression Free Survival ◽  
Chinese Patients ◽  
Line Treatment ◽  
Metastatic Colorectal Carcinoma ◽  
First Line ◽  
Oral Capecitabine ◽  
First Line Treatment

e15125 Background: The purpose of this study was to evaluate the safety and efficacy of the capecitabine-oxaliplatine combination (XELOX) in Chinese patients with metastatic colorectal carcinoma (mCRC). Furthermore, we aimed to explore whether a maintenance therapy with oral capecitabine in patients responding to XELOX is able to maintain the response and improve the duration of disease control (DDC). Methods: Patients with mCRC were treated with a 3-weekly regimen of oxaliplatin at a dose of 130 mg/m2 intravenously on Day 1 plus capecitabine 1000 mg/m2 orally twice daily from Days 2 to 15. Patients who did not progress after finished the XELOX therapy were choice to stop or receive oral capecitabine until disease progression or unacceptable toxicity. Results: 124 patients received a total of 637 cycles (median, 6) of treatment. Responses rate was 49.1%. Median overall and median progression-free survival was 20.0 months and 8.0 months, respectively. Main grade 3–4 drug-related toxicities included neutrapenia (5.6%), nausea/vomiting (4%), thrombocytopenia (2.4%), and hand-foot syndrome (2.4%). 23 of 101 patients responding to XELOX received oral capecitabine as maintenance therapy.The median DDC was 8 months for patients in the group of not using maintenance therapy, versus 12 months in the group of using capecitabine as maintenance therapy. Conclusions: XELOX is a highly effective first-line treatment for mCRC and provides a more convenient regimen, likely to be preferred by both patients and healthcare providers. Furthermore, these results support the feasibility of maintaining good response and improving DDC with oral Capecitabine after combination chemotherapy in mCRC. No significant financial relationships to disclose.

scholarly journals Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

Cancer ◽  
2004 ◽  
Vol 100 (2) ◽  
pp. 279-287 ◽  
Author(s):  
Emilio Bajetta ◽  
Maria Di Bartolomeo ◽  
Luigi Mariani ◽  
Antonio Cassata ◽  
Salvatore Artale ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Line Treatment ◽  
Metastatic Colorectal Carcinoma ◽  
First Line ◽  
Multicenter Phase ◽  
First Line Treatment

KRAS, NRAS and BRAF mutational status and first line treatment patterns in Slovenian population with metastatic colorectal carcinoma: Five year results.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15546-e15546
Author(s):  
Tanja Mesti ◽  
Marko Boc ◽  
Martina Rebersek ◽  
Zvezdana Hlebanja ◽  
Neva Volk ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Treatment Guidelines ◽  
Treatment Decision ◽  
Line Treatment ◽  
Wild Type ◽  
Metastatic Colorectal Carcinoma ◽  
First Line ◽  
Slovenian Population ◽  
Mutational Status ◽  
First Line Treatment

e15546 Background: A phase IV non-interventional study was performed from 2013 till 2018 including 650 patients with primary aim to assess KRAS, NRAS and BRAF mutational status in Slovenian population with metastatic colorectal carcinoma (mCRC) suitable for first-line treatment. The evaluation of decisions for first-line treatment regarding the biomarkers status and assessing the possible impact of the time period of the biomarker status analysis report on the treatment decision were also incorporated in the analysis. The molecular analyses for KRAS and NRAS gene mutations were performed on exons 2, 3 and 4, and for BRAF gene mutations on exon 15. The first line systemic treatment options for RAS (KRAS/NRAS) wild type (wt) and mutated type (mt) mCRC subjects were as follows: chemotherapy - Fluoropyrimidine based systemic therapy combined with oxaliplatin and/or irinotecan with/without VEGF inhibitor bevacizumab and for RAS wt subjects, with/without EGFR inhibitors, cetuximab or panitumumab. Methods: To indicate the degree of certainty of KRAS, NRAS and BRAF status frequency as being wild type or mutant type 95% confidence interval was calculated. Results: The KRAS/NRAS/BRAF mutation rates were as follows - The distribution of subjects with KRAS mutated and wild-type tumors, was almost equal, 48.8% and 47.9% respectively. Eighty nine percent of the subjects had NRAS wild type tumours and 86.1% had BRAF wild type tumours. The most frequently used treatment regardless the biomarkers status and in accordance with the treatment guidelines was bevacizumab based combination therapy (53.1%). The EGFR inhibitor (cetuximab or panitumumab) based combination therapy was used in one third of mCRC subjects (30.9%), all with mCRC RAS wt. The time period from the initial presentation of the patient until the biomarker status analysis report was two weeks. Conclusions: With this study, we have proven that the distribution of the mutations in exons 2-4 of KRAS and NRAS genes and exon 15 in the BRAF gene in the Slovenian population with metastatic colorectal cancer matches historical data. Based on this, we conclude that the treatment decision in Slovenian population with metastatic colorectal carcinoma should be in the accordance with international treatment guidelines and on evidence based medicine. The molecular analysis performed at the Institute of Oncology Ljubljana was providing necessary biomarkers status report in an acceptable time that didn’t affect the treatment decision or delay the needed cancer treatment.

Sign in / Sign up

Export Citation Format

Share Document